Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2018 - ResearchAndMarkets.com
Jun. 11, 2018
DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The "Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 4, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Companies MentionedAiCuris GmbH & Co KG Beech Tree Labs Inc NanoViricides Inc Shulov Innovative Science Ltd
Key Topics CoveredIntroduction Herpes Labialis (Oral Herpes) - Overview Herpes Labialis (Oral Herpes) - Therapeutics Development Herpes Labialis (Oral Herpes) - Therapeutics Assessment Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development Herpes Labialis (Oral Herpes) - Drug Profiles Herpes Labialis (Oral Herpes) - Dormant Projects Herpes Labialis (Oral Herpes) - Discontinued Products Herpes Labialis (Oral Herpes) - Product Development Milestones Appendix
For more information about this report visit https://www.researchandmarkets.com/research/dkbpsj/herpes_labialis?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005745/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs,Sexual and Reproductive Health Drugs
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/11/2018 10:42 AM/DISC: 06/11/2018 10:42 AM